

FIGURE 1




FIGURE 2

Compound 1 Treatment Demonstrated a Significantly Lower Mean Photon Count Compared to Vehicle Treatment




FIGURE 3

Real Time Monitoring in vivo KMS-11-luc MM Growth in SCID-beige Mice Treated with Vehicle or Compound 1 (20 mg/kg, p.o. daily)




FIGURE 4
Compound 1 Demonstrated Increased Survival Benefit Against
MM KMS-11-luc i.v. Model





FIGURE 5

FIGURE 6




FIGURE 7




FIGURE 8





FIGURE 9

FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14





FIGURE 15


FIGURE 16


FIGURE 17

FIGURE 18




FIGURE 19




FIGURE 20






FIGURE 21

FIGURE 22



Adapted from Grassot et al. Nucleic Acids Res. 2003 Jan 1; 31(1): 353-8.

FIGURE 23





FIGURE 24




FIGURE 25**a.****b.**

FIGURE 26

4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
Dosed Days 1-7, Off Days 8-14, Dosed Days 15-21, etc.

75 mg



- Strong inhibition of pERK detectable Day 1, 4 hr
- Inhibition maintained on Day 7, 4 and 24 hr
- Day 15; inhibition at 4 and 24 hr after dose